Forward P/S Multiple: Pulmonx Corp (LUNG)

Pulmonx - graphic logo of issuer LUNG

Despite a heavy reliance on external equipment assemblers, Pulmonx Corporation remains resilient. The forward P/S metric reflects the current market valuation, with the value stabilizing at 1.40. Stability is driven by the recognized Zephyr systems and contracts with US clinics, while professional management effectively scales sales while maintaining strict control over operating expenses.

Pulmonx - LUNG Market Cap to Projected Revenue (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Pulmonx (LUNG)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:LUNG (pulmonx.com)
Product sample of pulmonx.com

To minimize fundamental risks, investors select assets with a stable ratio of market capitalization to projected revenue, which allows for an assessment of the premium paid for future growth. The trend of the expected P/S multiple reflects market confidence in the scaling of the Pulmonx Corporation clinic network, where a decrease in the indicator may signal an undervaluation of the expansion of innovative valves in the US market.

Who Pulmonx Corporation competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|TELA Bio (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corp.)|Price-to-Projected Revenue Ratio sensushealthcare.com|Forward Price-to-Revenue Multiple Zynex, Inc. (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio inspira-technologies.com IINN|Price to Expected Revenue Ratio ICU (SeaStar Medical Holding Corp.)|IRIX: Forward Price-to-Revenue Multiple|ibs.inc - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|Future Price to Revenue PFSA (Profusa Inc.)|Forward Price-to-Revenue Multiple SSKN|Price-to-Projected Revenue Ratio GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Venus Concept - Market Cap to Projected Revenue|Forward P/S Multiple NUWE (Nuwellis Corp)|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)